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Abstract
Patients with adult-onset autoimmune diabetes have less Human Leucocyte Antigen (HLA)-associated genetic risk and
fewer diabetes-associated autoantibodies compared with patients with childhood-onset Type 1 diabetes. Metabolic
changes at diagnosis reflect a broad clinical phenotype ranging from diabetic ketoacidosis to mild non-insulin-requiring
diabetes, also known as latent autoimmune diabetes of the adult (LADA). This latter phenotype is the most prevalent
form of adult-onset autoimmune diabetes and probably the most prevalent form of autoimmune diabetes in general.
Although LADA is associated with the same genetic and immunological features as childhood-onset Type 1 diabetes, it
also shares some genetic features with Type 2 diabetes, which raises the question of genetic heterogeneity predisposing to
this form of the disease. The potential value of screening patients with adult-onset diabetes for diabetes-associated
autoantibodies to identify those with LADA is emphasized by their lack of clinically distinct features, their different
natural history compared with Type 2 diabetes and their potential need for a dedicated management strategy. The fact
that, in some studies, patients with LADA show worse glucose control than patients with Type 2 diabetes, highlights the
need for further therapeutic studies. Challenges regarding classification, epidemiology, genetics, metabolism,
immunology, clinical presentation and treatment of LADA were discussed at a 2014 workshop arranged by the Danish
Diabetes Academy. The presentations and discussions are summarized in this review, which sets out the current ideas
and controversies surrounding this form of diabetes.
Diabet. Med. 32, 843–852 (2015)
Introduction
Diabetes is a complex disease and the clinical classification
into Type 1 and Type 2 fails to capture the range of diseases
incorporated within the diagnosis [1]. Type 1a diabetes
(henceforth Type 1 diabetes) is believed to be an autoim-
mune disease characterized by genetic, immunological and
metabolic features. These features include an association
with genes within the major histocompatibility complex
(HLA), the presence of diabetes-associated autoantibodies
(DAA) and severe loss of insulin secretion, which can lead to
severe hyperglycaemia and ketoacidosis. The incidence is
highest in children, but adults also get the disease. In adult-
onset autoimmune diabetes, metabolic changes at diagnosis
reflect a broad phenotype ranging from diabetic ketoacidosis
to mild non-insulin-requiring diabetes. Alternative terms
that have been used to describe adult-onset autoimmune
Type 1 diabetes when it is not insulin dependent include:
latent autoimmune diabetes in adults (LADA), Type 1.5
diabetes, slowly progressive insulin-dependent diabetes mell-
itus or double diabetes. Recently, adult-onset autoimmune
diabetes with a positive T–cell response, but lacking DAA
has been described. Adult-onset autoimmune diabetes thus
encompasses a number of diabetic subgroups, Table 1.
Challenges regarding classification, epidemiology, genetics,
metabolism, immunology, clinical presentation and treat-
ment of adult-onset autoimmune diabetes with a focus on
LADA were discussed at a 2014 workshop arranged by the
Danish Diabetes Academy. The presentations and discus-
sions are summarized in this review, which sets out the
current ideas and controversies surrounding this form of
diabetes.
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How does adult-onset autoimmune diabetes
differ from Type 2 diabetes?
Epidemiology
Around 4–14% of patients classified with Type 2 diabetes
have DAA (Table 2 and Fig. 1) The frequency of
GADA-positive Type 2 diabetes is high in studies from
northern Europe (7–14% with decreasing prevalence by
increasing patient age) [2–5]. It appears to be lower in
southern Europe, Asia and North America (4–6%) [6–10]
and, within China, lower in the south than the north [8].
The frequency of DAA positivity is higher in hospital
settings than from a population-based ascertainment. These
discrepancies are dependent on biases including: selection
criteria, patient age at diagnosis, assays and disease
duration at study entry. In the Action LADA 7 study in
which adult patients with diabetes were tested, autoim-
mune diabetes was prevalent and those initially non-
insulin-requiring for six months (i.e. LADA) were far more
frequent than those requiring insulin treatment within a
month of diagnosis (i.e. ‘classic’ Type 1 diabetes; odds
ratio 3.3) [11]. By implication, adult-onset autoimmune
diabetes, including LADA, is more prevalent than child-
hood-onset Type 1 diabetes in Europe. In China, where
childhood-onset Type 1 diabetes is rare, the frequency
of LADA was found to be comparable with that in
Europe [8].
The three criteria conventionally used to define adult-
onset autoimmune diabetes are non-specific; namely, age at
diagnosis, autoantibody positivity and need for insulin
treatment. Definitions of adult age range from 15 to
30 years, extending to all ages or up to 70 years. Even
children aged less than 15 years with phenotypic Type 2
diabetes can have DAA and would be designated autoim-
mune diabetes. Autoantibody criteria lack specificity because
they are based on autoantibodies associated with childhood-
onset Type 1 diabetes, which lack 100% specificity, even in
the best laboratories [12]. These DAA include autoantibod-
ies to glutamic acid decarboxylase 65 (GADA), insulinoma-
associated antigen IA–2 (IA-2A), islet cells (ICA) and zinc
transporter 8 (ZnT8A). The definition of autoantibody
positivity is not unequivocal and different cut-off points
have been applied in different studies. Technically, false
positives may be limited by setting a higher cut-off or by
repeating positive measurements. Longitudinal studies
observe changing autoantibody status over time [3,13],
and even though the majority of patients are positive for
only one type of autoantibody, existing autoantibodies may
be lost and other autoantibodies may develop. The fluctu-
ating autoantibody status remains incompletely understood,
but potentially time-varying anti-idiotypic antibodies might
interfere in DAA assays [14]. The clinical significance of
borderline positivity remains unsettled. However, the term
‘false positive’ applied to changing autoantibody status
might be misleading, as even transient autoantibody posi-
tivity indicates a predisposition to autoimmunity. Recent
data even indicate that in some antibody-negative patients,
the diabetes may be autoimmune as defined by an islet-cell-
reactive T–cell response [15].
The need to start insulin treatment is usually physician
dependent given the infrequency of diabetic ketoacidosis,
now only found in the minority of children at diagnosis
[16]. Although there is no consensus regarding diagnostic
criteria, patients are generally designated as having adult-
onset autoimmune diabetes in the presence of DAA with an
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What’s new?
• Latent autoimmune diabetes of the adult (LADA) is an
autoimmune diabetes defined by adult-onset, presence
of diabetes associated autoantibodies, and no insulin
treatment requirement for a period after diagnosis.
• Immunologically, glutamic acid decarboxylase 65
autoantibodies are by far the most common autoanti-
body in adult-onset diabetes.
• LADA is the most prevalent form of adult-onset
autoimmune diabetes and probably the most prevalent
form of autoimmune diabetes in general.
• LADA shares genetic features with both type 1 and type
2 diabetes.
• Phenotypically, LADA patients are often misdiagnosed
as having type 2 diabetes.
• LADA patients generally have worse HbA1c levels than
type 2 diabetes patients.
• Clinically, LADA patients tend to have a lower mean
age at diabetes onset, lower body mass index and more
frequent need for insulin treatment than patients with
type 2 diabetes.
• Management of LADA may require a dedicated strat-
egy, yet currently there is a paucity of randomized
controlled trial data.
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adult age at diagnosis, irrespective of insulin treatment [17].
When the patients have DAA but do not require insulin
treatment for a period, usually six months, then they are
designated to have LADA. Arbitrary definitions of LADA
include a period without insulin treatment of at least
six months and an age at diagnosis of more than 30 years
[17,18].
Summary: knowledge and uncertainty
Adult-onset autoimmune diabetes is prevalent and likely far
more prevalent than childhood-onset Type 1 diabetes. Most
cases of adult-onset autoimmune diabetes are non-insulin
requiring, i.e. LADA. By any of its definitions, LADA
exists, the uncertainty is whether the underlying patho-
physiology is distinct from childhood-onset Type 1 diabetes
or is part of a clinical spectrum encompassing all forms of
autoimmune diabetes. It is not known whether the
burgeoning prevalence of Type 2 diabetes is associated
with an increasing prevalence of LADA. The simplest
position is to take all patients aged 18 years or more with
Type 1 diabetes and DAA as having adult-onset autoim-
mune diabetes, although their clinical phenotype defines the
clinical management.
Genetic features
Genome-wide association studies have identified many sus-
ceptibility loci predisposing to Type 1 diabetes [19–22] and
Type 2 diabetes [23–26]. A commonality to the genetic basis
of Types 1 and 2 diabetes has been suggested [27,28], but has
not been confirmed.
The strongest Type 2 diabetes genetic association was
identified within the transcription factor 7-like 2 (TCF7L2)
gene byGrant et al. in 2006 [29] and later replicated by others
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Zhou et al., Diabetes 2013 [8] 4880 287 (5.9) 287 (5.9) GADA 51.3 30 or
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FIGURE 1 Prevalence of patients with glutamic acid decarboxylase antibodies (GADA) among total number of patients diagnosed with type 2
diabetes.
ª 2015 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. 845
Review article DIABETICMedicine
in patients of European, Asian and African descent [30–32].
Conversely, this locus is widely accepted as not being associ-
ated with ‘classic’ childhood-onset Type 1 diabetes [28].
However, the risk-conferring variant within TCF7L2, is
similarly over-represented in adult-onset autoimmune diabe-
tes and Type 2 diabetes [33]. Genotyping of patients with
autoantibody-positive adult-onset autoimmune diabetes and
population-based controls at childhood-onset Type 1 diabetes
loci and the Type 2 diabetes/obesity riskmarkersTCF7L2 and
FTO has been performed. HLA, PTPN22, STAT4, CTLA4,
IL2RA and INSwere associated with autoimmune diabetes in
adults, as previously reported for paediatric Type 1 diabetes
[34]. HLA–DR3/4 was associated with a lower age at
diagnosis, and DR3 and DR4 were associated with GADA
and IA–2A positivity, respectively [34]. Phenotypically, it was
reported that high/intermediate-risk HLA genotypes were
associated with a significantly higher risk for the development
of insulin dependence compared with the low-risk HLA
genotype in patients with LADA [7]. However, even though
prevalence of HLA-DQB1 and PTPN22 risk genotypes were
increased in LADA, they were much less common than in
childhood-onset Type 1 diabetes [35].
The data suggest a genetic susceptibility continuum in
autoimmune diabetes extending from a marked effect in
childhood-onset Type 1 diabetes to a significant, but far less
pronounced effect of the same genes in LADA [18]. The lack
of HLA–DR3 and -DR4 heterozygotes in Chinese patients
might explain the very low incidence of childhood-onset
diabetes with HLA genes in this population, although
Chinese patients with LADA have moderate risk or protec-
tive HLA disease-associated variants [8].
Summary: knowledge and uncertainty
LADA has been associated with the same genetic features as
childhood-onset Type 1 diabetes (HLA, INS VNTR and
PTPN22) and Type 2 diabetes (TCF7L2) [36], which suggest
that it may represent a genetic admixture of the two types of
diabetes, especially when non-insulin requiring. The question
is whether such genetic admixture represents a distinct
disease syndrome or is part of an autoimmune continuum.
Genome-wide association studies targeting exome sequenc-
ing or whole-genome exome sequencing remain to be
conducted in large cohorts of adult-onset autoimmune
patients.
Metabolic features
Multiple studies have found that patients with LADA require
insulin treatment more frequently and earlier post diagnosis
than those with antibody-negative Type 2 diabetes. GADA
positivity in adult patients with non-insulin-requiring diabe-
tes is associated with decreased fasting C–peptide and a
decreased C–peptide response to oral glucose [2–4,8]. The
magnitude of this insulin response is inversely related to the
GADA titre [37]. Interestingly, in two large studies, insulin
secretion was similar in recently diagnosed patients with
LADA and Type 2 diabetes [10,38]. A detailed smaller
metabolic study of insulin secretion and insulin sensitivity
confirmed the lack of difference in weight-matched groups
with LADA and Type 2 diabetes [39]. However, despite
these early features, over time, the increased propensity for
reduced b–cell function in LADA becomes evident [2–4].
Patients with adult-onset autoimmune diabetes generally
have a better metabolic profile than those with Type 2
diabetes, with lower triglyceride, higher HDL cholesterol
levels, and lower BMI, waist-to-hip ratios and blood pressure
[6,8,11,37,40]. Within GADA-positive patients, these altered
metabolic parameters tend to be significantly better in those
with high-titre GADA compared with low-titre GADA, but
without a clear distinction between the groups [4,6,8,11].
These broad differences in metabolic parameters translate
into GADA-negative patients having more signs of metabolic
syndrome than GADA-positive patients, irrespective of
whether the latter have LADA or adult-onset Type 1 diabetes
[5,8,11]. Formal examination of insulin resistance indicates
that patients with LADA are more insulin insensitive than
healthy controls, but their insulin insensitivity is comparable
with or less than that of patients with Type 2 diabetes and is
dependent of BMI [10,39,41,42].
Summary: knowledge and uncertainty
Adult patients with DAA are more likely to have lower
C–peptide, fewer signs of metabolic syndrome, higher
HbA1c, progress to insulin therapy more rapidly and require
insulin treatment more often than do adult patients with
Type 2 diabetes without DAA. It remains unclear how DAA
is associated with the loss of insulin secretory capacity. Our
recommendation is not to manage diabetes based on the
knowledge of DAA alone.
Immunological features
Adult-onset Type 1 autoimmune diabetes is characterized by
less aggressive b–cell loss than childhood-onset autoimmune
diabetes, less HLA-associated genetic susceptibility and
fewer multiple autoantibodies.
Serum islet autoimmunity characterized by ICA in patients
classified with Type 2 diabetes was first described in 1977
[43]. Several studies have compared autoantibodies in
childhood- and adult-onset autoimmune diabetes. In general,
ICA, IAA, IA–2 and ZnT8 were more frequent in childhood-
onset than adult-onset autoimmune diabetes, whereas GADA
and IA–2256–760 were equally common [3,44–47]. GADA is
by far the most common autoantibody in adult-onset
diabetes (90% of positive cases) even in China where GADA
is less dominant [4,6,8,11]. After diagnosis of adult-onset
autoimmune diabetes, autoantibodies tend to disappear,
especially IA–2A and ZnT8A [3,13,48,49]. However, GADA
can still be detected in patients with apparent ‘Type 2’
diabetes some 12 years post diagnosis [5].
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A bimodal distribution of GADA titres has been reported
in several studies in patients with LADA diabetes, although
formal analysis for bimodality has not been made [6–8].
Other studies did not find such a bimodal distribution [4].
These apparent discrepancies may reflect differences in the
character of LADA in different populations and certainly in
China, the proportion of patients with high-titre GADA is
lower than in Europe [8]. Patients with high-titre GADA tend
to have high-affinity GADA and it appears that the b cell loss
is more rapid than in those with low-affinity GADA [50].
Data from the European Action LADA cohort (Action-
LADA) showed that adult-onset autoimmune patients,
whether they have ‘classic’ Type 1 diabetes or LADA, have
similar changes in systemic cytokines, chemokines and
adhesions molecules [51,52]. A large Chinese study reported
higher C–reactive protein and lower adiponectin in LADA
compared with adult-onset Type 1 diabetes [53]. In both
Chinese and European populations, there was a hierarchy of
differences in systemic inflammation (e.g. interleukin–6) such
that serum levels were highest in Type 2 diabetes compared
with autoimmune diabetes (whether LADA or ‘classic’
Type 1), and lowest in healthy controls [51,53].
Small studies have described differences in LADA with
regard to abnormal DNA methylation in CD4 + T cells in
LADA [54], alteredT–regulatory cells [55],NKcells [56], gene
expression profiles of monocytes [57] and some antigen-
reactive T cells [58,59]. However, these data require confir-
mation and other studies have not shown differences in T cells
upon stimulation with different islet-associated antigens [60].
It is generally accepted that T cells are largely responsible for
the inflammatory pancreatic b–cell destruction in autoimmune
diabetes. Yet we know little of this response and even less in
LADA. A T–cell assay of cellular immunoblotting measuring
reactivity to human islet antigens using peripheral blood
demonstrated excellent specificity and sensitivity, comparable
withDAA, in distinguishing between blood frompatients with
childhood-onset Type 1 diabetes and normal controls [61,62].
Intriguingly, using this T–cell assay, a proportion of patients
with phenotypic Type 2 diabetes showed T–cell reactivity
comparable with that seen in patients with Type 1 diabetes
[63]. The implicationswere emphasized by confirmation that a
percentage of patients with autoantibody-negative ‘Type
2’ diabetes have distinct T–cell reactivity to islet antigens and
that T–cell reactivitywasmore closely associatedwith reduced
C–peptide than DAA [15]. These observations need to be
confirmed in other laboratories and there is no evidence that
the T cells are strictly autoimmune. However, they certainly
challenge the conventional perception that only Type 1
diabetes is due to an ‘autoimmune’ process.
Summary: knowledge and uncertainty
Adult-onset autoimmune diabetes and childhood-onset
Type 1 diabetes are barely distinguishable immunologically,
although the latter has a greater immunogenetic load with
more multiple DAA, more frequent IA–2A and ZnT8A, plus
lower C–peptide and more rapid C–peptide loss. High-titre
GADA in the former is associated with multiple DAA, high-
affinity GADA and with greater loss of C–peptide. In adult-
onset autoimmune diabetes, the dominant autoantibody is
GADA [50,64]. In childhood, GADA tends to appear later
(about age 5 years) than IAA (about age 2 years) [65]. It is
not known when GADA associated with LADA first
appears and whether GADA found in childhood might
predict autoimmune diabetes developing 20 or more years
later. The pathophysiological significance of patients with
Type 2 diabetes having T–cell islet immunoreactivity, even
when they are negative for GADA and other DAA, is not
known.
Clinical features
At diagnosis, the clinical phenotype in patients with autoim-
mune diabetes is remarkably broad, ranging from diabetic
ketoacidosis to diabetes that can be controlled with diet alone.
The classification of these patients also covers a range that can
appear arbitrary; for example, in the European Action LADA
study, patients with GADA and started on insulin within one
month of diagnosis were designated classic Type 1 diabetes,
those started on insulin within six months were unclassified
and those started on insulin at six months or later were
designated LADA. By comparison with those with Type 2
diabetes, patients with adult-onset autoimmune diabetes, even
when non-insulin requiring (LADA), tend to have a lower age
at diabetes onset, lowerBMI andwaist-to-hip ratio, but amore
pronounced loss of C–peptide and an increased likelihood of
insulin treatment [2,8,11]. Substantial heterogeneity is also
observed within patients who are GADA positive. Phenotyp-
ically, high-titre GADA patients tend to have these same
characteristics, but these aremoremarked andmore similar to
classic Type 1 diabetes, patients being younger at diagnosis,
leaner with a high risk of progression to insulin treatment.
Low-titre GADA patients are phenotypically more similar to
those with Type 2 diabetes. These differences are also
captured by the metabolic syndrome, which is more prevalent
in Type 2 diabetes than Type 1 diabetes and LADA, andmore
prevalent in low-titre than high-titre GADA patients
[2,4,6,8,11]. Because high-titre GADA tends to be associated
with multiple DAA, it is not surprising that the NIRAD study
found that among patients with adult-onset diabetes, themore
DAA were detected the more these patients needed insulin
treatment and had younger age at onset [47].However, there is
sufficient overlap for these clinical parameters between groups
of patients to make it impossible to accurately distinguish
adult-onset autoimmune diabetes from Type 2 diabetes on
clinical features alone when considering individual patients
[66,67].
Summary: knowledge and uncertainty
There are no clear clinical features that distinguish autoim-
mune diabetes from Type 2 diabetes. However, there is a
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tendency for adult patients with GADA, even when non-
insulin requiring, to be younger at diagnosis and leaner with
a greater tendency to progress to insulin treatment. Within a
cohort of GADA-positive adult patients, the GADA titre and
the number of DAA impact the clinical and biochemical
differences from Type 2 diabetes. Clinical phenotype should
drive management strategy.
Does it matter that LADA is different from
Type 2 diabetes?
Clinical presentation
It is highly debatable if GADA should be measured in all
patients with diabetes. Screening strategies differ widely,
both internationally and regionally, ranging from mandatory
screening at some university hospitals to patient-driven or
sponsored screening at other sites.
In favour of general screening of adult patients with
diabetes, patients with Type 2 and LADA cannot be iden-
tified by any single clinical feature short of diabetic ketoac-
idosis. However, the data are conflicting regarding the
predictive value of GADA positivity for incident diabetes
[14,38,68–71].
Disease progression
Need for insulin treatment
GADA positivity is strongly associated with subsequent
insulin requirement [72]. In the UKPDS, 84% of GADA-
positive patients vs 14% of GADA-negative patients received
insulin treatment by six years after diagnosis [3]. In the
Nord-Trøndelag Health Study (HUNT) the numbers were
40% vs 22% 14 years after diagnosis [2]. In the Collabora-
tive Atorvastatin Diabetes Study (CARDS) 56% and 17% of
GADA-positive and -negative patients, respectively, received
insulin at baseline, and 16% vs 5% insulin-na€ıve patients at
baseline began insulin treatment during 3.9 years of follow-
up [5]. Awareness of patients having LADA might result in
more frequent and focused follow-up and an earlier start for
insulin treatment if metabolic decompensation develops.
Data from studies with the available newer, second-line
antidiabetic drugs suggest that these may postpone loss of b-
cell function [73–75].
Blood glucose control
Despite greater use of insulin, patients with LADA tend to
have worse glycaemic control than those with Type 2
diabetes [5,76,77], although this difference in China this
difference was not evident [8]. More patients with LADA
(68%) than patients with Type 2 diabetes (53%) had poor
glycaemic control — defined as HbA1c > 52 mmol/mol
( > 6.9%) — during 107 months of follow-up [76]. Early
insulin therapy does not seem to improve control [78].
Diabetes microvascular and macrovascular complications
The prevalence of microvascular complications in LADA is
broadly similar to that seen in patients with Type 2 diabetes,
although a lower risk of nephropathy was reported in the
small Freemantle study [5,79–81].
Patients with LADA generally have a more favourable
cardiovascular risk profile than those with Type 2 diabetes.
However, studies to date have not found evidence for a lower
risk of macrovascular disease in patients with LADA
[5,79,80]. Despite the fact that these studies were small,
there is no evidence to support a less-aggressive treatment
policy for cardiovascular risk factors in patients with LADA.
Summary: knowledge and uncertainty
Because it is not possible to identify patients with LADA
without screening, there might be value in routine GADA
screening. However, even in Europe where awareness of the
issue is relatively high, screening is not performed
consistently. A substantial proportion of patients with LADA
do not require insulin after many years of disease, which calls
into question the strategy of initiating all GADA-positive
patients on insulin at diagnosis. Conversely, in patients on
insulin, glycaemic control is suboptimal, suggesting that
insulin alone may not be sufficient. So before clinical trial
data are available to direct specific therapy, it is important to
identify autoimmune diabetes cases to focus on their quality
of control.
Co-morbidities with LADA
Patients with LADA, compared with those with Type 2
diabetes, are characterized by a higher prevalence of other
autoimmune diseases, especially thyroid disease [82]. In the
Italian NIRAD studies of LADA, patients had a higher
frequency of thyroid peroxidase antibodies (TPO) (27%)
compared with patients with GADA-negative diabetes
(10.5%) [6]; those with a high GADA titre had a higher
frequency of TPO antibodies compared with those patients
with low GADA titre [83].
Summary: knowledge and uncertainty
The risk of thyroid autoimmunity and, by implication,
thyroid disease is substantially higher in patients with LADA
than in those with Type 2 diabetes. Monitoring thyroid
function more closely in such patients, and potentially
screening for other autoimmune diseases, may be important
in their management.
Management strategies
There is a marked paucity of data regarding the treatment of
patients with LADA.
Despite its widespread use as primary treatment in Type 2
diabetes, there are no controlled studies on the effects of
848
ª 2015 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
DIABETICMedicine LADA – knowledge and uncertainty  E. Laugesen et al.
metformin alone in patients with LADA [84]. The theoretical
risk of treating diabetic ketoacidosis-prone patients with
biguanide is, in clinical practice, very low in adults. Gliben-
clamide and insulin were compared in patients with LADA in
two randomized controlled Japanese trials. The sulfonylurea
group in one pilot study had worse metabolic control and
more rapid deterioration of C–peptide secretion compared
with insulin treatment at 30 months follow-up [85]; this was
confirmed by the second study [86]. Therefore, sulfonylureas
should not be used as first-line therapy in patients with
LADA. Insulin sensitizers, such as thiazolidinediones, might
potentially be of interest. One small study in China
supported their use when combined with insulin in preserv-
ing islet b–cell function in LADA, yet these agents are not
currently widely used [87].
Instead attention has focused on the use of dipeptidyl
peptidase–4 (DPP–4) inhibitors.
Three DPP–4 inhibitors (sitagliptin, linagliptin and saxag-
liptin) have been studied in patients with LADA in three
trials, two of them reported as abstracts of retrospective
analyses [73,75] and the other, a prospective study [74]. In
the prospective study, Chinese patients with LADA were
given insulin glargine and randomized to either sitagliptin or
placebo. Sitagliptin-treated patients had a minimal and
insignificant decline in C–peptide over one year, whereas
the placebo-treated group had a significant decrease. The
two-hour C–peptide level in the sitagliptin-treated patients
was significantly higher than in the placebo-treated patients
at 12 months [74]. Whether DPP–4 inhibitors alter b–cell
function, independent of their acute insulin-stimulating
action, remains unknown.
Summary: knowledge and uncertainty
To date, the evidence indicates that patients with LADA
should be treated with insulin as a first choice when
glycaemic control deteriorates to a level indicating need for
antiglycaemic treatment. There is no evidence either for or
against the use of metformin, although sulfonylureas are
positively discouraged. The role of DPP–4 inhibitors remains
to be determined. This strategy contrasts with the current
treatment of non-insulin-requiring Type 2 diabetes. How-
ever, evidence is not strong and large prospective randomized
trials are required.
Immune therapy
Theoretically, immunotherapy in antibody-positive patients
might prevent or modify the underlying disease process. Yet,
in childhood-onset Type 1 diabetes, immunological
approaches have had limited success at reducing the loss of
C–peptide secretion. Agents that have been shown to be of
benefit include cyclosporine (an inhibitor of T–cell activa-
tion), Abatacept (a CTLA–4 inhibitor), Rituximab (anti-
CD20) and anti-CD3 monoclonal antibodies. As reviewed by
Larsson and Lernmark, these immunosuppressive drugs
generally lose their disease-modifying capacities quite rapidly
[88]. In addition, they have negative side effects, e.g.
cyclosporine A can cause kidney damage [89].
In Type 1 diabetes, treatment with GAD had divergent
results with a positive Phase 2 study antedating two unsuc-
cessful Phase 3 studies [90–92]. A safety study of patients
with LADA using the GAD-alum formulation, however, did
show a relative preservation of C–peptide secretion in
response to a mixed-meal, which was sustained after
five years [93].
Summary: knowledge and uncertainty
In summary, an immunological approach is logical in LADA,
but only one small study has been finished. In that study a
GAD-alum formulation had a beneficial effect without
adverse side effects, even after five years. Theoretically, a
high GADA titre might be of the least benefit, for in that
same GAD-alum study it was those patients with low GADA
affinity, and by implication low GADA titre, who had
prolonged preservation of C–peptide secretion [50]. This
field is open to development and no immunotherapy is
currently offered clinically to any patients with autoimmune
diabetes outside research trials.
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